Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chidamide + BEAM
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Chidamide + BEAM is a combination therapy that pairs chidamide, a histone deacetylase (HDAC) inhibitor, with the BEAM conditioning regimen (carmustine, etoposide, cytarabine, and melphalan) used in autologous stem cell transplantation (ASCT) for lymphoma patients. Chidamide is a subtype-selective HDAC inhibitor targeting HDAC1, 2, 3, and 10, acting as an epigenetic regulator. It leads to cell cycle inhibition and apoptosis in tumor cells. The BEAM regimen is a standard high-dose chemotherapy protocol used before ASCT. The combination is being evaluated in a prospective Phase II trial for relapsed/refractory lymphoma, aiming to improve outcomes compared to standard ASCT conditioning.
- Other names
- Chi-BEAM RegimenChidamide + BEAMC-BEAM Regimen
02
Targets
HDAC1 (Histone Deacetylase 1)HDAC10 (Histone Deacetylase 10)
Beyond the preview
Go deeper on chidamide + BEAM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chidamide + BEAM.